Financials data is unavailable for this security.
View more
Year on year Charmacy Pharmaceutical Co Ltd had net income fall -43.25% from 90.47m to 51.34m despite a 5.47% increase in revenues from 4.18bn to 4.40bn. An increase in the selling, general and administrative costs as a percentage of sales from 3.19% to 3.22% was a component in the falling net income despite rising revenues.
| Gross margin | 6.91% |
|---|---|
| Net profit margin | 1.15% |
| Operating margin | 1.60% |
| Return on assets | 1.70% |
|---|---|
| Return on equity | 8.88% |
| Return on investment | 8.48% |
More ▼
Cash flow in CNYView more
In 2023, Charmacy Pharmaceutical Co Ltd increased its cash reserves by 63.99%, or 44.07m. Cash Flow from Financing totalled 101.26m or 2.30% of revenues. In addition the company used 96.54m for operations while cash from investing totalled 39.34m.
| Cash flow per share | 0.8093 |
|---|---|
| Price/Cash flow per share | 11.49 |
| Book value per share | 5.90 |
|---|---|
| Tangible book value per share | 5.10 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.07 |
|---|---|
| Quick ratio | 0.7714 |
| Total debt/total equity | 1.43 |
|---|---|
| Total debt/total capital | 0.5882 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -31.97% and -43.25%, respectively. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 3.39% |
|---|---|
| Div growth rate (5 year) | 0.00% |
| Payout ratio (TTM) | 0.00% |
| EPS growth(5 years) | 2.48 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -46.20 |
More ▼
